ClinicalTrials.Veeva

Menu

Norwegian Spontaneous Coronary Artery Dissection Study (NOR-SCAD)

University of Oslo (UIO) logo

University of Oslo (UIO)

Status

Enrolling

Conditions

SCAD
Women
Myocardial Infarction (MI)

Study type

Observational

Funder types

Other

Identifiers

NCT07317323
853139
ProCardio (Other Identifier)

Details and patient eligibility

About

The Norwegian Spontaneous Coronary Artery Dissection Study (NOR-SCAD) is a national, multicenter prospective observational study conducted at major hospitals in Norway. The study investigates risk factors and complications of spontaneous coronary artery dissection (SCAD). Patients aged 18 years or older who are hospitalized with SCAD are recruited during the index hospitalization. Each participant will be followed for 52 weeks with scheduled visits at 8 and 12 weeks and a final phone call at 52 weeks. Evaluations include coronary CT angiography (CTA), cardiac assessments, genetic analyses, blood sampling, structured questionnaires, and a cardiopulmonary exercise test (CPET).

Full description

Background: SCAD has emerged as an important cause of myocardial infarction, especially among women under 60 years of age, and is a leading cause of pregnancy-related myocardial infarction. Despite increased awareness over the past two decades, SCAD remains under-recognized, and management varies widely because of limited evidence. Key gaps persist in understanding SCAD etiology, precipitating factors, optimal diagnostic follow-up (including the role of CTA), and the incidence of complications.

Objectives:

Primary objectives: Determine the incidence and types of complications and major adverse cardiac events (MACE) within the first year after SCAD.

Secondary objectives: Evaluate the diagnostic and follow-up utility of coronary CTA.

Methods:

  • Multicenter prospective observational cohort study.
  • Enrollment period: 2025-2035.
  • Study population: Adults (≥18 years) hospitalized with angiographically or imaging-confirmed SCAD at participating hospitals in Norway.
  • Follow-up duration: 52 weeks per participant.

Study visits and procedures:

  1. Week 1: Acute hospitalization with CT index and blood samples
  2. Week 8: CT control
  3. Week 12: Comprehensive physical examination with cardiac exams, blood samples, CPET
  4. Week 52: Final follow-up phone call to assess clinical events

Endpoints includes major cardiac events (MACE), CTA findings and quality of life.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Spontaneous coronary artery dissection

Exclusion criteria

  • Severe kidney failure
  • Severe allergic reaction to contrast

Trial design

300 participants in 1 patient group

Prospective
Description:
SCAD

Trial contacts and locations

3

Loading...

Central trial contact

Anna Louise Astad Sørlie, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems